SCHEMBL17100657

SCHEMBL17100657

CCOc1ccc(S(=O)(=O)N2CCN(c3nc(C4(c5cccc(Cl)c5)CC4)no3)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
LMNA P02545 3/20 0.44
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
GBA1 P04062 1/20 0.43
GAA P10253 3/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TSHR P16473 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPK1 P28482 2/20 0.42
YAP1 P46937 1/20 0.41
TEAD4 Q15561 1/20 0.41
TEAD2 Q15562 1/20 0.41
APOBEC3A P31941 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100705 0.91 ALDH1A1 (0.49) MEN1KMT2ALMNAPOLBNPSR1
SCHEMBL17100628 0.90 TDP1 (0.52) MEN1KMT2ATDP1LMNAPOLB
SCHEMBL17100701 0.90 KMT2A (0.53) MEN1KMT2ATDP1LMNAPOLB
SCHEMBL17100587 0.87 POLB (0.38) MEN1KMT2ALMNAPOLBL3MBTL1
SCHEMBL17100694 0.85 TSHR (0.40) MEN1KMT2ALMNAPOLBL3MBTL1
SCHEMBL17100650 0.84 KMT2A (0.49) MEN1KMT2ALMNAPOLBL3MBTL1
SCHEMBL17100715 0.80 L3MBTL1 (0.50) MEN1KMT2ATDP1LMNAPOLB
SCHEMBL17100888 0.80 L3MBTL1 (0.50) MEN1KMT2ATDP1LMNAPOLB
SCHEMBL17100658 0.80 ALDH1A1 (0.55) MEN1KMT2ALMNAPOLBGAA
SCHEMBL17100675 0.80 ALDH1A1 (0.55) KMT2ALMNAPOLBGBA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT MEN1 2665/4885KMT2A 4820/4885TDP1 327/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT MEN1 2837/4885KMT2A 4819/4885TDP1 349/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT MEN1 2665/4885KMT2A 4820/4885TDP1 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.